See more : E3 Lithium Limited (ETL.V) Income Statement Analysis – Financial Results
Complete financial analysis of Yuhan Corporation (000105.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Yuhan Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Biotech Acquisition Company (BIOTU) Income Statement Analysis – Financial Results
- RaySearch Laboratories AB (publ) (RSLBF) Income Statement Analysis – Financial Results
- PT Gudang Garam Tbk (GGNPF) Income Statement Analysis – Financial Results
- Canzon Israel Ltd (CNZN.TA) Income Statement Analysis – Financial Results
- Jiangxi Guoguang Commercial Chains Co., Ltd. (605188.SS) Income Statement Analysis – Financial Results
Yuhan Corporation (000105.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.yuhan.co.kr
About Yuhan Corporation
Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury; ETC products in the areas of cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems; anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics. It also offers OTC products, including vitamins and minerals, hepatopathy drugs and tonics, respiratory system drugs, alimentary system drugs, dermatology and analgesics drugs, and others; and household and healthcare products, such as bleaches, detergents, pesticides, and oral care products. In addition, the company engages in dental business and offers implants, dental equipment/consumable, and dental care products. Additionally, the company manufactures and sells medical supplies for livestock, aquatic animals, and household pets. Further, it provides contract manufacturing services. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,858.98B | 1,775.85B | 1,687.81B | 1,619.87B | 1,480.35B | 1,518.82B | 1,462.25B | 1,320.80B | 1,128.73B | 1,017.49B | 943.61B | 776.46B | 679.23B | 663.57B | 646.77B | 611.19B | 493.29B |
| Cost of Revenue | 1,294.47B | 1,257.65B | 1,163.16B | 1,061.44B | 1,049.50B | 1,105.03B | 1,037.62B | 931.36B | 788.06B | 702.06B | 649.84B | 530.89B | 426.19B | 387.89B | 357.49B | 319.96B | 249.70B |
| Gross Profit | 564.51B | 518.20B | 524.65B | 558.42B | 430.85B | 413.79B | 424.62B | 389.44B | 340.67B | 315.44B | 293.77B | 245.57B | 253.04B | 275.68B | 289.28B | 291.23B | 243.58B |
| Gross Profit Ratio | 30.37% | 29.18% | 31.08% | 34.47% | 29.10% | 27.24% | 29.04% | 29.49% | 30.18% | 31.00% | 31.13% | 31.63% | 37.25% | 41.54% | 44.73% | 47.65% | 49.38% |
| Research & Development | 119.92B | 107.10B | 106.68B | 142.63B | 96.90B | 74.07B | 71.43B | 52.67B | 39.02B | 30.92B | 32.03B | 24.74B | 28.68B | 21.41B | 16.33B | 16.41B | 13.59B |
| General & Administrative | 28.48B | 27.71B | 27.10B | 25.18B | 28.49B | 25.60B | 20.67B | 19.55B | 19.62B | 19.54B | 20.89B | 20.39B | 19.68B | 21.89B | 22.16B | 18.45B | 15.75B |
| Selling & Marketing | 162.06B | 172.69B | 163.41B | 129.58B | 133.89B | 119.34B | 118.69B | 105.16B | 84.90B | 88.05B | 87.02B | 80.03B | 70.68B | 66.86B | 74.11B | 90.04B | 75.14B |
| SG&A | 370.03B | 200.40B | 190.51B | 154.76B | 162.38B | 144.94B | 139.36B | 124.70B | 104.52B | 107.59B | 107.91B | 100.42B | 90.36B | 88.74B | 96.26B | 108.49B | 90.89B |
| Other Expenses | 0.00 | 174.67B | 178.87B | 176.78B | 159.03B | -3.53B | 21.77B | 4.64B | -1.19B | 1.20B | 7.23B | 10.11B | 83.85B | 5.38B | -7.77B | 1.30B | -9.91B |
| Operating Expenses | 489.95B | 482.17B | 476.05B | 474.17B | 418.32B | 363.67B | 335.91B | 291.65B | 254.83B | 241.04B | 231.93B | 210.97B | 202.89B | 193.03B | 202.93B | 208.25B | 171.95B |
| Cost & Expenses | 1,784.42B | 1,739.82B | 1,639.21B | 1,535.61B | 1,467.82B | 1,468.70B | 1,373.54B | 1,223.00B | 1,042.89B | 943.10B | 881.77B | 741.86B | 629.08B | 580.93B | 560.42B | 528.21B | 421.65B |
| Interest Income | 11.15B | 9.58B | 5.01B | 6.80B | 12.36B | 13.23B | 9.33B | 9.57B | 11.59B | 12.20B | 12.57B | 16.11B | 16.27B | 15.32B | 11.72B | 13.03B | 8.29B |
| Interest Expense | 2.46B | 3.47B | 2.94B | 2.71B | 3.10B | 3.67B | 4.62B | 5.33B | 3.13B | 2.08B | 790.12M | 477.47M | 518.77M | 514.00M | 604.81M | 1.45B | 3.33B |
| Depreciation & Amortization | 44.68B | 43.02B | 52.67B | 59.78B | 58.66B | 59.00B | 52.20B | 42.92B | 31.06B | 26.51B | 18.90B | 17.43B | 17.78B | 21.55B | 25.39B | 22.91B | 21.62B |
| EBITDA | 127.43B | 78.07B | 123.92B | 238.89B | 69.65B | 109.13B | 201.73B | 140.71B | 116.89B | 100.91B | 80.74B | 124.95B | 82.73B | 165.07B | 162.71B | 169.37B | 129.81B |
| EBITDA Ratio | 6.86% | 8.42% | 11.42% | 11.85% | 8.30% | 10.02% | 14.13% | 18.98% | 18.19% | 16.01% | 15.29% | 15.67% | 18.65% | 24.24% | 25.55% | 27.55% | 26.42% |
| Operating Income | 74.56B | 106.46B | 140.03B | 132.24B | 64.28B | 50.13B | 88.71B | 97.79B | 85.84B | 74.39B | 61.84B | 34.60B | 49.04B | 82.64B | 86.35B | 82.98B | 71.64B |
| Operating Income Ratio | 4.01% | 5.99% | 8.30% | 8.16% | 4.34% | 3.30% | 6.07% | 7.40% | 7.60% | 7.31% | 6.55% | 4.46% | 7.22% | 12.45% | 13.35% | 13.58% | 14.52% |
| Total Other Income/Expenses | 23.66B | -11.53B | -13.97B | 107.65B | -9.37B | 39.26B | 56.21B | 107.10B | 82.51B | 41.70B | 45.29B | 72.44B | 57.83B | 60.37B | 50.36B | 62.03B | 33.22B |
| Income Before Tax | 98.22B | 94.93B | 126.06B | 239.89B | 54.92B | 89.39B | 144.92B | 204.89B | 168.35B | 116.10B | 107.12B | 107.04B | 106.86B | 143.01B | 136.71B | 145.01B | 104.85B |
| Income Before Tax Ratio | 5.28% | 5.35% | 7.47% | 14.81% | 3.71% | 5.89% | 9.91% | 15.51% | 14.91% | 11.41% | 11.35% | 13.79% | 15.73% | 21.55% | 21.14% | 23.73% | 21.26% |
| Income Tax Expense | 4.71B | 4.33B | 26.93B | 49.49B | 18.31B | 31.06B | 35.28B | 43.64B | 42.30B | 25.15B | 20.66B | 26.27B | 12.65B | 15.01B | 14.97B | 19.36B | 12.78B |
| Net Income | 93.51B | 95.14B | 102.58B | 192.76B | 40.01B | 57.48B | 109.03B | 161.25B | 126.05B | 90.95B | 86.46B | 80.78B | 94.22B | 128.00B | 121.74B | 125.64B | 92.07B |
| Net Income Ratio | 5.03% | 5.36% | 6.08% | 11.90% | 2.70% | 3.78% | 7.46% | 12.21% | 11.17% | 8.94% | 9.16% | 10.40% | 13.87% | 19.29% | 18.82% | 20.56% | 18.67% |
| EPS | 1.17K | 1.27K | 1.36K | 2.55K | 553.86 | 831.92 | 1.59K | 2.34K | 1.74K | 1.25K | 1.17K | 1.10K | 1.24K | 1.64K | 1.54K | 1.63K | 1.17K |
| EPS Diluted | 1.19K | 1.27K | 1.36K | 2.55K | 553.86 | 831.92 | 1.59K | 2.34K | 1.74K | 1.25K | 1.17K | 1.10K | 1.24K | 1.64K | 1.54K | 1.59K | 1.17K |
| Weighted Avg Shares Out | 79.95M | 75.18M | 75.59M | 75.74M | 72.23M | 69.09M | 68.38M | 68.80M | 72.29M | 72.81M | 73.63M | 73.65M | 74.71M | 77.83M | 78.84M | 76.91M | 78.68M |
| Weighted Avg Shares Out (Dil) | 78.71M | 75.18M | 75.59M | 75.74M | 72.23M | 69.09M | 68.38M | 68.80M | 72.29M | 72.81M | 73.63M | 73.65M | 74.71M | 77.83M | 78.85M | 78.89M | 78.96M |
Source: https://incomestatements.info
Category: Stock Reports